沈涤非
心内
院长助理，三级主任医师，副教授，硕士生导师
院长助理，三级主任医师，副教授，硕士生导师
导师介绍
| 姓名 | 沈涤非 |
| 出生年月 | 1976年9月 |
| 单位 | 武汉大学人民医院心血管内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 院长助理，三级主任医师，副教授，硕士生导师 |
| rm000137@whu.edu.cn | |
| 联系方式 | 027-88041911转86731或1397105…… |
| 研究方向 |
1.心肌重构的发生机制2.心力衰竭的防治 |
| 个人简介 | 主要从事心血管疾病的诊治与科研工作，获国家自然科学基金2项、新疆维吾尔自治区省科技厅科技支疆项目1项、作为研究骨干参与国家重点研发计划项目1项，参与国家自然基金项目5项，武汉市重点科研攻关项目1项。发表学术论文40余篇，其中SCI论文17篇，参编著作3部。 |
| 学术任职与荣誉 | 中华医学会心血管病学分会心血管临床研究学组委员、中国医师协会心血管病分会双心学组委员、中国心衰中心联盟专家委员会常委、中国医促会心血管病分会委员、海医会老年医学专业委员会青年委员学会常委，湖北省医院协会常务理事，武汉市科学技术协会委员、《心肺血管病杂志》编委。 |
| 教育履历 |
1995.09-2006.06武汉大学第一临床学院临床医学专业本科生获学士学位 2001.09-2004.06武汉大学生物医学工程硕士研究生获硕士学位 2004.09-2007.06武汉大学第一临床学院内科学博士研究生获博士学位 |
| 工作履历 |
2007.08-2011.01 武汉大学人民医院心血管内科主治医师、讲师 2011.01-2012.01 武汉大学人民医院心血管内科,副主任医师、讲师 2012.01-2016.12 武汉大学人民医院心血管内科副教授、副主任医师（其中，2014.09-2016.03,作为中组部第八批援疆干部人才，在新疆医科大学第五附属医院担任党委委员、副院长） 2016.12-至今 武汉大学人民医院心血管内科主任医师、副教授，院长助理（其中，2016.10至2018.10，作为武汉大学人民医院外派干部，在潜江市中心医院担任院长、党委副书记） |
| 成果获奖 |
1.《心力衰竭的结构重构及其防治》2019年获湖北省科技进步一等奖 2.《心肌重构的发病基础与临床防治》2013年湖北省科技进步一等奖 |
| 代表性论著 |
1.
Li N, Wang W, Zhou H, Wu Q, Duan M, Liu C, Wu H, Deng W, Shen D(*), Tang
Q(*). Ferritinophagy-mediated ferroptosis is involved in sepsis-induced
cardiac injury. Free Radic Biol Med,
2020 ;160:303-318. 2. Song P(#), Shen DF(#), Meng YY(#), Kong CY, Zhang X, Yuan YP, Yan L, Tang QZ, Ma ZG. Geniposide protects against sepsis-induced myocardial dysfunction through AMPKα-dependent pathway. Free Radic Biol Med, 2020, 152:186-196. 3. Yuan Y, Wang J, Chen Q, Wu Q, Deng W, Zhou H, Shen DF(*). Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling. Biochim Biophys Acta Mol Basis Dis, 2019;1865:1421. 4. Che Y(#), Shen DF(#), Wang ZP, Jin YG, Wu QQ, Wang SS, Yuan Y. Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. BMC Cardiovasc Disord, 2019;19:219. 5. Wang ZP(#), Shen DF(#), Che Y, Jin YG, Wang SS, Wu QQ, Zhou H, Meng YY, Yuan Y. Corosolic acid ameliorates cardiac hypertrophy via regulating autophagy. Biosci Rep, 2019;39. 6. Wang J, He W, Guo L, Zhang Y, Li H, Han SX(*), Shen DF(*). The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction, MOL MED REP, 2017;16:1973. 7. Wang J, He W, Xu X, Guo L, Zhang Y, Han SX(*), Shen DF(*). The mechanism of TGF-beta/miR-155/c-Ski regulates endothelial-mesenchymal transition in human coronary artery endothelial cells, Biosci Rep, 2017;37. 8. Shen DF(#), Wu QQ(#), Ni J, Deng W, Wei C, Jia ZH, Zhou H, Zhou MQ, Bian ZY, Tang QZ. Shensongyangxin protects against pressure overload induced cardiac hypertrophy, MOL MED REP, 2016;13:980. 9. Shen DF(#), Ni J, Wu QQ, Deng W, Wei C, Jia ZH, Zhou H, Zhou MQ, Bian ZY, Tang QZ, Shensongyangxin protects cardiomyocytes against LPS-inducedinjury through the NF kappa B pathway, International Journal of Clinical and Experimental Medicine, 2016, 9(2): 2317-2324 |
| Name | DIFEI SHEN |
| Date of birth | September，1978 |
| Department | Cardiovascular Department，Renmin Hospital,Wuhan University. |
| Title | Assistant dean, Associate professor , Chief physician |
| rm000137@whu.edu.cn | |
| TEL | 027-88041911-86731 |
| Research Direction |
1.
Mechanism of cardiac remodeling 2. Prevention and treatment of heart failure |
| Personal Profile | He is mainly engaged in the diagnosis and treatment of cardiovascular diseases,and has been awarded 2 items for the National Natural Science Foundation, 1 items from the Science and technology support project of science and Technology Department of Xinjiang Uygur Autonomous Region. As a research backbone, he participated in one national key R & D project, five national natural fund projects, and one Wuhan key scientific research project. He has published more than 40 academic papers, including 17 SCI papers and 3 books. |
| Selected Publications |
1.
Li N, Wang W, Zhou H, Wu Q, Duan M, Liu C, Wu H, Deng W, Shen D(*), Tang
Q(*). Ferritinophagy-mediated ferroptosis is involved in sepsis-induced
cardiac injury. Free Radic Biol Med,
2020 ;160:303-318. 2. Song P(#), Shen DF(#), Meng YY(#), Kong CY, Zhang X, Yuan YP, Yan L, Tang QZ, Ma ZG. Geniposide protects against sepsis-induced myocardial dysfunction through AMPKα-dependent pathway. Free Radic Biol Med, 2020, 152:186-196. 3. Yuan Y, Wang J, Chen Q, Wu Q, Deng W, Zhou H, Shen DF(*). Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling. Biochim Biophys Acta Mol Basis Dis, 2019;1865:1421. 4. Che Y(#), Shen DF(#), Wang ZP, Jin YG, Wu QQ, Wang SS, Yuan Y. Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. BMC Cardiovasc Disord, 2019;19:219. 5. Wang ZP(#), Shen DF(#), Che Y, Jin YG, Wang SS, Wu QQ, Zhou H, Meng YY, Yuan Y. Corosolic acid ameliorates cardiac hypertrophy via regulating autophagy. Biosci Rep, 2019;39. 6. Wang J, He W, Guo L, Zhang Y, Li H, Han SX(*), Shen DF(*). The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction, MOL MED REP, 2017;16:1973. 7. Wang J, He W, Xu X, Guo L, Zhang Y, Han SX(*), Shen DF(*). The mechanism of TGF-beta/miR-155/c-Ski regulates endothelial-mesenchymal transition in human coronary artery endothelial cells, Biosci Rep, 2017;37. 8. Shen DF(#), Wu QQ(#), Ni J, Deng W, Wei C, Jia ZH, Zhou H, Zhou MQ, Bian ZY, Tang QZ. Shensongyangxin protects against pressure overload induced cardiac hypertrophy, MOL MED REP, 2016;13:980. 9. Shen DF(#), Ni J, Wu QQ, Deng W, Wei C, Jia ZH, Zhou H, Zhou MQ, Bian ZY, Tang QZ, Shensongyangxin protects cardiomyocytes against LPS-inducedinjury through the NF kappa B pathway, International Journal of Clinical and Experimental Medicine, 2016, 9(2): 2317-2324 |
武汉大学人民医院
湖北省人民医院